SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCOS.L Regulatory News (COS)

  • There is currently no data for COS

Half Yearly Report

10 Dec 2013 07:00

RNS Number : 1046V
Healthcare Investment Opportunities
10 December 2013
 



Healthcare Investment Opportunities plc

 

Unaudited Statement of Comprehensive Income

for the six months to 30 September 2013

 

Healthcare Investment Opportunities plc (AIM: HIO), an investment company focusing on the healthcare sector, is pleased to announce its inaugural set of unaudited interim results for the six month period ended 30 September 2013. These have been posted to shareholders today and are available on the Company's website at www.healthcareinvestmentopps.co.uk.

 

Commenting on the results, David Evans, Chairman of Healthcare Investment Opportunities plc said:

 

"Since HIO listed on AIM in April 2013, both the board and myself have been actively reviewing acquisition opportunities, and have looked at over 30 opportunities in this time. We are delighted that the proposed acquisition of Collbio Limited was announced earlier this morning and are confident that the acquisition will be value enhancing for shareholders if the transaction is approved at the general meeting scheduled for 27 December 2013."

 

Enquiries:

 

Healthcare Investment Opportunities Plc

David Evans, Chairman

 

Tel: 07740 084 452

Zeus Capital (Nominated Adviser and Broker)

Corporate Finance

Ross Andrews

John Depasquale

Tel: 0161 831 1512

 

Institutional Sales

John Goold

Dominic Wilson

 

 

Tel: 020 7533 7727

Tel: 020 7533 7721

Walbrook PR Ltd

Tel: 020 7933 8780 or hio@walbrookpr.com

Paul McManus 

Mike Wort

Mob: 07980 541 893

 

 

 

Unaudited Statement of Comprehensive Income

6 months to 30 September 2013

£

Continuing operations

Administrative expenses

(62,631)

OPERATING LOSS

(62,631)

Interest receivable and similar income

-

LOSS BEFORE TAXATION

(62,631)

Tax on loss on ordinary activities

-

LOSS FOR THE PERIOD

(62,631)

 

Other comprehensive income, net of tax

-

TOTAL COMPREHENSIVE LOSS FOR THE PERIOD ATTRIBUTABLE TO OWNERS OF THE PARENT

(62,631)

 

LOSS PER ORDINARY SHARE (PENCE)

Basic

(Note 2)

(0.15)p

Diluted

(Note 2)

(0.15)p

 

 

Unaudited Statement of Changes in Equity

 for the six month period to 30th September, 2013

 

 

Share

Share

premium

Retained

Total

capital

account

earnings

Equity

£

£

£

£

(Loss) for the six month period

-

-

(62,631)

(62,631)

Funds raised

405,000

3,645,000

-

4,050,000

Issue expenses

-

(360,060)

-

(360,060)

At 30th September, 2013

405,000

3,284,940

(62,631)

3,627,309

 

 

Unaudited Statement of Financial Position

as at 30th September 2013

 

 

£

As at 30 September 2013

ASSETS

Current assets

Cash and cash equivalents

3,632,309

3,632,309

TOTAL ASSETS

3,632,309

LIABILITIES

Current liabilities

Trade and other payables

5,000

NET CURRENT ASSETS

3,627,309

NET ASSETS

3,627,309

TOTAL EQUITY

Called up share capital

405,000

Share premium account

3,284,940

Retained earnings

(62,631)

3,627,309

 

 

 

Unaudited Cash Flow Statement

for the six month period to

30th September 2013

 

 

6 months

30 September 2013

£

Cash flows from operating activities

Operating (loss) for the period

(62,631)

Increase in trade and other payables

5,000

Cash generated from operations

(57,631)

Income taxes received

-

Net cash used in operating activities

(57,631)

Cash flows from financing activities

Proceeds from issue of share capital

4,050,000

Expenses of share issue

(360,060)

Net cash generated from financing activities

3,689,940

Net increase in cash and cash equivalents

3,632,309

Cash and cash equivalents at end of the period

3,632,309

 

 

 

 

Notes to the Interim Financial Statements

for the period to 30th September, 2013

 

1 Basis of preparation

 

The interim financial statements have been prepared in accordance with the AIM rules and on the basis of all International Financial Reporting Standards ("IFRS") as adopted by the European Union that are expected to be applicable to the Company's statutory accounts for the year ended 31st March 2014. The interim financial statements are unaudited and were approved by the Directors on 9 December 2013. The information set out herein is abbreviated and does not constitute statutory accounts within the meaning of Section 434 of the Companies Act 2006.

 

The Company has not applied IAS 34, Interim Financial Reporting, which is not mandatory for UK Groups, in the preparation of these interim financial statements.

 

The Company is a limited liability company incorporated and domiciled in England & Wales and whose shares are quoted on AIM, a market operated by The London Stock Exchange. The financial information of Healthcare Investment Opportunities plc is presented in Pounds Sterling (£), which is also the functional currency of the Company.

 

 

2 Loss per share

 

Basic loss per share, from continuing operations, is calculated by dividing the earnings attributable to ordinary shareholders by the weighted average number of ordinary shares outstanding during the year.

 

The calculations of earnings per share are based on the following losses and numbers of shares.

 

6 months to

30 September 2013

 

Loss after taxation (62,631)

 

Weighted average number of shares 40,500,000

 

Basic earnings per share (0.15)p

 

At 30th September, 2013 the Company had 40,500,000 Ordinary Shares of 1p in issue.

 

The loss for the period and the weighted average number of ordinary shares for calculating the diluted earnings per share for the six months ended 30 September 2013 are identical to those used for the basic earnings per share.

 

3 Interim results

 These results were approved by the Board of Directors on 9 December 2013.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IR DDBDDCDGBGXC
Date   Source Headline
12th Sep 20167:00 amRNSIssue of Equity
24th Aug 201611:26 amRNSResult of AGM
25th Jul 201611:48 amRNSPosting of Annual Report
19th Jul 20167:15 amRNSHardman research: Focused scalable growth
15th Jul 20167:00 amRNSGrant of Options
12th Jul 20165:12 pmRNSDirector/PDMR Shareholding
12th Jul 201611:51 amRNSHolding(s) in Company
11th Jul 20164:15 pmRNSDirector/PDMR Shareholding
11th Jul 20163:16 pmRNSDirector/PDMR Shareholding
11th Jul 20167:00 amRNSFinal Results
13th Jun 20167:00 amRNSNotice of Results Investor Presentation
4th May 20167:00 amRNSDirectorate Change
3rd May 20167:00 amRNSLeadership changes and preliminary FY revenue
27th Apr 20165:34 pmRNSHolding(s) in Company
26th Apr 20168:28 amRNSJoint Venture Agreement in China
19th Apr 20167:00 amRNSSupply of collagen materials to Merck
30th Mar 20169:37 amRNSHolding(s) in Company
23rd Mar 20167:00 amRNSResearch collaboration
26th Feb 20161:02 pmRNSHolding(s) in Company
12th Feb 20167:00 amRNSDeath of adviser
3rd Feb 20167:00 amRNSCollagen Solutions present at The Scotsman
22nd Jan 20165:47 pmRNSHolding(s) in Company
21st Jan 201610:14 amRNSChairman's Share Purchase
20th Jan 20167:00 amRNSTrading Update
14th Jan 20165:29 pmRNSHolding(s) in Company
9th Dec 201511:17 amRNSHolding(s) in Company
9th Dec 20157:00 amRNSHardman Issues Research Report
7th Dec 20157:00 amRNSCollagen Solutions Supply Agreement with BBI
2nd Dec 20153:48 pmRNSDirector/PDMR Shareholding
1st Dec 20157:00 amRNSHalf Yearly Report
20th Nov 20153:20 pmRNSDeath of a Director
18th Nov 20157:00 amRNSAppointment of Chief Business Officer
3rd Nov 20157:00 amRNSNotice of Results
28th Sep 20157:00 amRNSCollagen supply agreement to Yucel Medical
22nd Sep 20157:00 amRNSMedical Research Studentship
16th Sep 20157:00 amRNSSupply Agreement with Histogenics Corporation
14th Sep 20157:00 amRNSAcquisition of a regenerative medicine product
3rd Sep 20157:00 amRNSFDA approval for NovaBone product
28th Aug 201510:11 amRNSAGM Statement
28th Aug 20157:00 amRNSJoins consortium developing new treatments
22nd Jul 20157:00 amRNSPosting of Annual Report & Notice of AGM
15th Jul 201510:09 amRNSHardman & Co issues research on Collagen Solutions
14th Jul 20157:00 amRNSPartnership with UCL and Oxford MEStar Ltd
13th Jul 20157:00 amRNSFinal Results
3rd Jul 20152:11 pmRNSNotice of Results
26th Jun 20157:00 amRNSChange of Adviser
22nd Jun 20157:00 amRNSInnovate UK Grant Award
28th May 20157:00 amRNSNew Patent Granted
17th Apr 20151:53 pmRNSHardman & Co issues research report
14th Apr 20157:00 amRNSUK Investor Show attendance

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.